HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT
Paris, January 14, 2015 - Neovacs (Alternext Paris : ALNEV) releases its six-monthly report on the liquidity contract signed with Invest Securities.
The liquidity account had the following holdings as of December 31, 2014:
- 76,340 shares
- €110,086.43
For the prior (June 30, 2014), the corresponding figures were:
- 15,631 shares
- €213,136.66
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
Contacts
Néovacs
Nathalie Trépo
+33 (0) 53 10 93 00
ntrepo@neovacs.com
Publicis
Stéphanie Tabouis
Aubane de Gelis
+33 (0)1 44 82 46 38
aubane.de-gelis@consultants.publicis.fr
